Yarrow Bioscience IncYARW
▼ NegativeCapitalrelevance
GAAP EPS miss of $2.14 vs expectations
Impact on stocks 1
Biotech & Genomic Medicine
Yarrow Bioscience IncYarrow Bioscience IncVYNE Therapeutics reported a second-quarter GAAP loss of $2.14 per share, missing expectations by $1.92. As of June 30, 2026, the company had cash and cash equivalents of $18.7 million. Yarrow expects its cash position, together with $100 million received in July 2026 from the second half of the pre-merger private financings, to fund operations into 2028.
Yarrow Bioscience IncGAAP EPS miss of $2.14 vs expectations